While NRAS and TP53 mutations are substantially more prevalent in type B2 and B3 thymomas and thymic carcinomas, mutations in the HRAS gene are primarily restricted to type A and AB thymomas [48,49]. This evidence concerns the gene HRAS and thymoma.